Caveolin-1 in sarcomas: friend or foe?

Miguel Sáinz-Jaspeado; Juan Martin-Liberal; Laura Lagares-Tena; Silvia Mateo-Lozano; Xavier Garcia del Muro; Oscar M. Tirado

doi:10.18632/oncotarget.255

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

Caveolin-1 in sarcomas: friend or foe?

Miguel Sáinz-Jaspeado, Juan Martin-Liberal, Laura Lagares-Tena, Silvia Mateo-Lozano, Xavier Garcia del Muro and Oscar M. Tirado _

PDF | HTML | How to cite

Oncotarget. 2011; 2:305-312. https://doi.org/10.18632/oncotarget.255

Metrics: PDF 2773 views | HTML 3983 views | ?

Abstract

Miguel Sáinz-Jaspeado¹, Juan Martin-Liberal¹, Laura Lagares-Tena¹, Silvia Mateo-Lozano², Xavier Garcia del Muro¹ and Oscar M Tirado¹

¹Sarcoma Research Group, IDIBELL (Bellvitge Biomedical Research Institute), L'Hospitalet de Llobregat, Barcelona, Spain

²Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM-Nanomedicine, Vall d'Hebron Hospital Research Institute, Barcelona, Spain

Keywords: Caveolin-1, Sarcomas, Oncogene, Tumor suppressor

Received: March 31, 2011; Accepted: April 1, 2011; Published: April 2, 2011;

Correspondence:

Oscar M. Tirado, e-mail:

Abstract

Sarcomas represent a heterogeneous group of tumors with a complex and difficult reproducible classification. Their pathogenesis is poorly understood and there are few effective treatment options for advanced disease. Caveolin-1 is a multifunctional scaffolding protein with multiple binding partners that regulates multiple cancer-associated processes including cellular transformation, tumor growth, cell death and survival, multidrug resistance, angiogenesis, cell migration and metastasis. However, ambiguous roles have been ascribed to caveolin-1 in signal transduction and cancer, including sarcomas. In particular, evidence indicating that caveolin-1 function is cell context dependent has been repeatedly reported. Caveolin-1 appears to act as a tumor suppressor protein at early stages of cancer progression. In contrast, a growing body of evidence indicates that caveolin-1 is up-regulated in several multidrug-resistant and metastatic cancer cell lines and human tumor specimens. This review is focused on the role of caveolin-1 in several soft tissue and bone sarcomas and discusses the use of this protein as a potential diagnostic and prognostic marker and as a therapeutic target.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 255

Publication Alerts

Research Perspectives:

Caveolin-1 in sarcomas: friend or foe?

Abstract